Mindstate Design Labs

Mindstate Design Labs is a clinical-stage AI neuroengineering and pharmaceutical company founded in 2021, based in South San Francisco, California, with additional operations in Pi

ttsburgh, Pennsylvania. The company focuses on developing precision-designed psychedelic-inspired therapeutics to address the mental health crisis. By utilizing artificial intelligence, Mindstate maps the biological basis of psychedelic experiences to engineer novel small-molecule drugs that create specific therapeutic mindstates without unwanted hallucinations. The company's lead program, MSD-001, is currently in human Phase 1 clinical trials and aims to produce heightened emotional and cognitive flexibility. Mindstate's proprietary AI platform, Osmanthus, synthesizes extensive datasets to design psychoactive compounds that yield repeatable, therapeutically valuable states of mind. Mindstate primarily serves the mental health therapeutics sector, targeting healthcare institutions and patients with challenging mental health conditions. Their vision is to provide therapeutically valuable emotions in pharmaceutical form, offering a targeted alternative to traditional mental health treatments.